Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amsterdam wins European Medicines Agency After Milan Loses Coin Toss In Tight Race

Executive Summary

London has lost the European Medicines Agency to Amsterdam after the Dutch capital beat Milan in a voting process that ended in the drawing of lots. The Italian pharmaceutical industry was understandably disappointed at losing, but the EMA said the decision “ticked a lot of our boxes” and would help to keep down staff losses and ensure business continuity.

You may also be interested in...



Merck's UK Proposal: What's Attracting the US Giant To London For Innovation?

Merck & Co. will build a new innovation hub in London – an act described by the UK government as a major strategic investment – despite widespread Brexit ambiguity and a potentially unstable economic situation ahead for the soon-to-be ex-EU nation.

EMA Discloses Staff’s Preferred Host Cities, Amid Fears Relocation Could Batter Its Budget

The EMA has published its analysis of the 19 bids to host the agency post-Brexit, which confirms reports that five cities – Amsterdam, Barcelona, Copenhagen, Milan and Vienna – would bring the best result in terms of retaining staff when it relocates. The agency has expressed concern that low retention rates could hit operations and result in lower fee income, requiring an injection of cash from the EU budget.

UK/EU Industry ‘Still Working In The Dark’ On Post-Brexit Regulation

As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.

Topics

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel